Pachyonychia Congenita Clinical Trial
Official title:
Simvastatin Treatment of Pachyonychia Congenita
Simvastatin and related statins, such as compactin, are able to inhibit the constitutive
expression of inducible/repressible keratin genes such as K6a and K17. This effect is due to
the reported ability of statins to inhibit STAT1 expression (Lee et al., 2007). The
constitutive K6a promoter activity is dependent on STAT1 and blocked by simvastatin or siRNA
against STAT1. This STAT1-dependent constitutive expression of K6a, is independent of JAK
(Janus family of kinases).
Thus simvastatin is capable of down-regulating both the constitutive and
interferon-inducible expression of PC-related keratins such as K6a and K17. Therefore, this
class of molecule has potential for the treatment of PC or related inherited disorders where
the causative mutation resides in an inducible/repressible keratin gene such as K6a or K17.
Simvastatin or other statins approved for human use might be delivered either orally, as is
currently the case for cholesterol-lowering treatment or, if higher therapeutic doses are
required in skin for reduction of hyperkeratosis in PC or in related keratinizing disorders,
this might be achieved by topical formulations.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02592954 -
Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin
|
Phase 1 | |
| Active, not recruiting |
NCT04520750 -
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
|
Phase 3 | |
| Recruiting |
NCT05180708 -
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
|
Phase 3 | |
| Recruiting |
NCT05643872 -
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
|
Phase 3 | |
| Recruiting |
NCT05956314 -
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC
|
Phase 1 | |
| Recruiting |
NCT05435638 -
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases
|
Phase 1 | |
| Completed |
NCT02152007 -
Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
|
Phase 1 | |
| Completed |
NCT00716014 -
Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita
|
Phase 1 | |
| Recruiting |
NCT02321423 -
International Pachyonychia Congenita Research Registry
|
||
| Active, not recruiting |
NCT03920228 -
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
|
Phase 2/Phase 3 |